William Blair Weighs in on ResMed’s Q3 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Research analysts at William Blair cut their Q3 2025 EPS estimates for ResMed in a note issued to investors on Monday, February 3rd. William Blair analyst M. Andrew now forecasts that the medical equipment provider will post earnings of $2.32 per share for the quarter, down from their prior forecast of $2.37. The consensus estimate for ResMed’s current full-year earnings is $9.41 per share. William Blair also issued estimates for ResMed’s FY2026 earnings at $10.23 EPS.

A number of other equities analysts have also weighed in on the stock. Piper Sandler boosted their price objective on shares of ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Royal Bank of Canada upped their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. UBS Group raised shares of ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, January 31st. Finally, KeyCorp upped their price target on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average price target of $244.73.

ResMed Stock Performance

NYSE:RMD opened at $237.11 on Thursday. The firm has a 50 day simple moving average of $239.68 and a 200-day simple moving average of $237.19. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The firm has a market cap of $34.81 billion, a PE ratio of 27.99, a P/E/G ratio of 1.69 and a beta of 0.70. ResMed has a 1-year low of $170.56 and a 1-year high of $263.05.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed’s payout ratio is currently 25.03%.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Justin Leong sold 6,160 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the completion of the transaction, the insider now owns 21,718 shares of the company’s stock, valued at $5,279,428.62. This trade represents a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,094 shares of company stock valued at $2,704,941 over the last 90 days. Corporate insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. True Wealth Design LLC boosted its stake in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in ResMed during the 3rd quarter valued at $34,000. BankPlus Trust Department bought a new position in ResMed during the 4th quarter valued at $44,000. Rosenberg Matthew Hamilton bought a new position in ResMed during the 4th quarter valued at $54,000. Finally, Capital Performance Advisors LLP bought a new position in ResMed during the 3rd quarter valued at $60,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.